Cardio Diagnostics Holdings Inc (CDIO) - Net Assets
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has net assets worth $6.97 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.77 Million) and total liabilities ($793.06K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CDIO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.97 Million |
| % of Total Assets | 89.79% |
| Annual Growth Rate | 158.58% |
| 5-Year Change | 552.87% |
| 10-Year Change | N/A |
| Growth Volatility | 635.1 |
Cardio Diagnostics Holdings Inc - Net Assets Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's net assets have evolved over time, based on quarterly financial data. See Cardio Diagnostics Holdings Inc (CDIO) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual net assets of Cardio Diagnostics Holdings Inc from 2020 to 2025. For live valuation and market cap data, see Cardio Diagnostics Holdings Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.97 Million | -27.04% |
| 2024-12-31 | $9.56 Million | +223.10% |
| 2023-12-31 | $2.96 Million | -31.23% |
| 2022-12-31 | $4.30 Million | +302.74% |
| 2021-12-31 | $1.07 Million | +1669.42% |
| 2020-12-31 | $60.37K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cardio Diagnostics Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2853988700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.00 | 0.00% |
| Other Components | $36.22 Million | 519.45% |
| Total Equity | $6.97 Million | 100.00% |
Cardio Diagnostics Holdings Inc Competitors by Market Cap
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Noronex Ltd
AU:NRX
|
$5.42 Million |
|
BetterLife Pharma Inc
F:NPAU
|
$5.42 Million |
|
Strike Resources Ltd
AU:SRK
|
$5.42 Million |
|
Trainers House Oyj
HE:TRH1V
|
$5.42 Million |
|
Adalta Ltd
AU:1AD
|
$5.41 Million |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
$5.41 Million |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
$5.40 Million |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
$5.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cardio Diagnostics Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,557,788 to 6,973,354, a change of -2,584,434 (-27.0%).
- Net loss of 6,498,167 reduced equity.
- New share issuances of 3,803,498 increased equity.
- Other factors increased equity by 110,235.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.50 Million | -93.19% |
| Share Issuances | $3.80 Million | +54.54% |
| Other Changes | $110.23K | +1.58% |
| Total Change | $- | -27.04% |
Book Value vs Market Value Analysis
This analysis compares Cardio Diagnostics Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 312.10x to 0.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.01 | $1.98 | x |
| 2021-12-31 | $3.37 | $1.98 | x |
| 2022-12-31 | $1.39 | $1.98 | x |
| 2023-12-31 | $7.00 | $1.98 | x |
| 2024-12-31 | $0.36 | $1.98 | x |
| 2025-12-31 | $3.98 | $1.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cardio Diagnostics Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -93.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -43832.49%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-93.19%) is above the historical average (-272.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -1002.51% | 0.00% | 0.00x | 7.39x | $-611.20K |
| 2021 | -58.09% | -68862.15% | 0.00x | 1.03x | $-727.26K |
| 2022 | -108.35% | -490630.00% | 0.00x | 1.45x | $-5.09 Million |
| 2023 | -283.18% | -49087.81% | 0.00x | 1.51x | $-8.67 Million |
| 2024 | -87.71% | -24028.24% | 0.00x | 1.11x | $-9.34 Million |
| 2025 | -93.19% | -43832.49% | 0.00x | 1.11x | $-7.20 Million |
Industry Comparison
This section compares Cardio Diagnostics Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cardio Diagnostics Holdings Inc (CDIO) | $6.97 Million | -1002.51% | 0.11x | $5.42 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more